Humanized Mice in Tumor Studies

Humanized mice, which harbor human immune cells, can be induced in response to treatment with immune checkpoint inhibitors. Recently, these models have been adapted for the testing of compounds that manipulate the immune system to help fight cancer, as one drawback of patient-derived and traditional xenografts is the lack of an immunologically competent host.

Charles River offers two study platforms using humanized mouse models (NOG, NSG, and the new NCG) engrafted with CD34+ or PBMC. Our models have been characterized with known immune checkpoint inhibitors of clinical relevance to help take the next step in evaluating your compound in immuno-oncology. We have validated our patient-derived xenograft models as well as our human xenograft portfolio.

Request Model Data »

CD34+ PBMC
HSC derived from umbilical cord; multiple donors in each cohort. A single cohort of animals can engraft with a single donor.
~Week 15: > 25% huCD45 blood cells Week 3: ~30% huCD45 blood cells
T cell focused T cell focused
Long-term studies (no GvHD) Short-term studies due to GvHD
Number of T cells may vary with multiple donors GvHD onset varies with donor
  Less costly approach

These models can be combined with a variety of tools to enhance your study outcomes, such as:

You may also be interested in...

Poster Download

View our poster that outlines our evaluation of the efficacy of the checkpoint inhibitors pembrolizumab and ipilimumab in the human RKO colon carcinoma xenograft model in CD34-NSG humanized mice.

Webinar Replay

Learn more about the advances we have made in the humanized mouse system.

Presentation Slides

View our presentation slides on combination immune checkpoint inhibitors for the treatment of colon carcinoma in humanized mice.

Webinar Replay

View our webinar about our studies on both PDX and traditional xenograft mouse models, evaluating the response to immune checkpoint inhibitors in humanized mouse models.